194 related articles for article (PubMed ID: 36474006)
1. Prognostic predictors of remission in ocular myasthenia gravis.
Çelebisoy N; Orujov A; Balayeva F; Özdemir HN; Ak AK; Gökçay F
Acta Neurol Belg; 2023 Oct; 123(5):1927-1932. PubMed ID: 36474006
[TBL] [Abstract][Full Text] [Related]
2. Thymectomy in ocular myasthenia gravis-prognosis and risk factors analysis.
Zhang J; Zhang Z; Zhang H; Cui Y; Chen Y; Lv P; Zhang P
Orphanet J Rare Dis; 2022 Aug; 17(1):309. PubMed ID: 35945595
[TBL] [Abstract][Full Text] [Related]
3. Ophthalmologic manifestations in myasthenia gravis: presentation and prognosis.
Akan O; Baysal-Kirac L
Acta Neurol Belg; 2021 Oct; 121(5):1131-1140. PubMed ID: 33439450
[TBL] [Abstract][Full Text] [Related]
4. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.
Kupersmith MJ; Ying G
Br J Ophthalmol; 2005 Oct; 89(10):1330-4. PubMed ID: 16170126
[TBL] [Abstract][Full Text] [Related]
5. Single-fiber Electromyography in the Extensor Digitorum Communis for the Predictive Prognosis of Ocular Myasthenia Gravis: A Retrospective Study of 102 Cases.
Guan YZ; Cui LY; Liu MS; Niu JW
Chin Med J (Engl); 2015 Oct; 128(20):2783-6. PubMed ID: 26481746
[TBL] [Abstract][Full Text] [Related]
6. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
[TBL] [Abstract][Full Text] [Related]
7. Ophthalmologic clinical features of ocular myasthenia gravis.
Kim DH; Roh HC; Oh SY
Medicine (Baltimore); 2023 Jan; 102(2):e31972. PubMed ID: 36637960
[TBL] [Abstract][Full Text] [Related]
8. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Kupersmith MJ; Latkany R; Homel P
Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics and outcomes of myasthenia gravis patients with double positive antibodies against acetylcholine receptor and muscle-specific tyrosine kinase].
Lu YR; Yu L; Ma Q; Chen P; Qiu L; Ou CY; Lin ZZ; Liu WB
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):942-947. PubMed ID: 35385966
[No Abstract] [Full Text] [Related]
10. Response to treatment of myasthenia gravis according to clinical subtype.
Akaishi T; Suzuki Y; Imai T; Tsuda E; Minami N; Nagane Y; Uzawa A; Kawaguchi N; Masuda M; Konno S; Suzuki H; Murai H; Aoki M; Utsugisawa K
BMC Neurol; 2016 Nov; 16(1):225. PubMed ID: 27855632
[TBL] [Abstract][Full Text] [Related]
11. The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis.
Nikolic A; Djukic P; Basta I; Hajdukovic Lj; Stojanovic VR; Stevic Z; Nikolic D; Bozic V; Lavrnic S; Lavrnic D
Clin Neurol Neurosurg; 2013 Apr; 115(4):432-7. PubMed ID: 22770539
[TBL] [Abstract][Full Text] [Related]
12. Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis.
Nakata R; Motomura M; Masuda T; Shiraishi H; Tokuda M; Fukuda T; Ando T; Yoshimura T; Tsujihata M; Kawakami A
Eur J Neurol; 2013 Sep; 20(9):1272-6. PubMed ID: 23679930
[TBL] [Abstract][Full Text] [Related]
13. Adult Ocular Myasthenia Gravis Conversion: A Single-Center Retrospective Analysis in China.
Feng X; Huan X; Yan C; Song J; Lu J; Zhou L; Wu H; Qiao K; Lu J; Xi J; Luo S; Zhao C
Eur Neurol; 2020; 83(2):182-188. PubMed ID: 32526733
[TBL] [Abstract][Full Text] [Related]
14. Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic.
Kısabay A; Özdemir HN; Gökçay F; Çelebisoy N
Acta Neurol Belg; 2022 Apr; 122(2):337-344. PubMed ID: 33544334
[TBL] [Abstract][Full Text] [Related]
15. Clinical Features, Treatment, and Prognostic Factors of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort.
Bi Z; Ge H; Zhang Q; Gao H; Yang M; Zhan J; Lin J; Gui M; Li Y; Ji S; Cao Y; Bu B
Pediatr Neurol; 2023 Sep; 146():31-39. PubMed ID: 37421800
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of Repetitive Ocular Vestibular-Evoked Myogenic Potentials to Diagnose Myasthenia Gravis in Patients With Ptosis or Diplopia.
Valko Y; Wirth MA; Fierz FC; Schesny MK; Rosengren S; Schmückle-Meier T; Bockisch CJ; Straumann D; Schreiner B; Weber KP
Neurology; 2024 May; 102(10):e209395. PubMed ID: 38669629
[TBL] [Abstract][Full Text] [Related]
17. Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma.
De Rosa A; Fornili M; Maestri Tassoni M; Guida M; Baglietto L; Petrucci L; Chella A; Melfi F; Lucchi M; Ricciardi R
Thorac Cancer; 2021 Jan; 12(1):106-113. PubMed ID: 33142021
[TBL] [Abstract][Full Text] [Related]
18. Onset and Evolution of Clinically Apparent Myasthenia Gravis After Resection of Non-myasthenic Thymomas.
Mineo TC; Tamburrini A; Schillaci O; Ambrogi V
Semin Thorac Cardiovasc Surg; 2018; 30(2):222-227. PubMed ID: 29522809
[TBL] [Abstract][Full Text] [Related]
19. Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?
Monte G; Spagni G; Damato V; Iorio R; Marino M; Evoli A
J Neurol; 2021 May; 268(5):1803-1807. PubMed ID: 33387011
[TBL] [Abstract][Full Text] [Related]
20. Inferior oblique muscle paresis as a sign of myasthenia gravis.
Almog Y; Ben-David M; Nemet AY
J Clin Neurosci; 2016 Mar; 25():50-3. PubMed ID: 26531848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
